Study:
Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Luorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug may kill more tumor cells. It is
not yet known which chemotherapy regimen is more effective for stage III colon cancer.
Purpose:
Randomized phase III trial to compare the effectiveness of fluorouracil plus
leucovorin with or without irinotecan in treating patients who have undergone surgery for
stage III colon cancer.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Colorectal Cancer |
Drug: FOLFIRI regimen
Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium |
Phase 3 |
Verified by
Cancer and Leukemia Group B
November, 2012
Sponsored by: Cancer and Leukemia Group B
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00003835
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Leonard B. Saltz, MD., Study Chair
Richard M. Goldberg, MD., Study Chair
David J. Klaassen, MD., Study Chair
Alexander Hantel, MD., Study Chair
James P. Thomas, MD, PhD., Study Chair